Related Experiment Video
Updated: May 22, 2026
06:40
Cost-Efficient Transcriptomic-Based Drug Screening
Published on: February 23, 2024
Do companion diagnostics make economic sense for drug developers?
1tangram@sloan.mit.edu
New Biotechnology
|May 12, 2012
Summary
Personalized medicine, using companion diagnostics, offers varied outcomes for drug developers. Analyzing historical case studies reveals strategies for successful implementation and avoiding pitfalls.
Area of Science:
- Biotechnology
- Pharmacology
- Medical Diagnostics
Background:
- Personalized medicine, combining molecular diagnostics with targeted therapies, presents challenges for drug development portfolios.
- The definition of companion diagnostics, requiring pre-prescription diagnostic testing, encompasses over 50 drugs across various therapeutic areas.
- Historical data from these drugs offer insights into diverse market situations and commercialization strategies.
Purpose of the Study:
- To analyze historical case studies of companion diagnostics to guide drug developers.
- To evaluate the impact of companion diagnostics on drug portfolios and commercialization strategies.
- To identify successful strategies and potential pitfalls in companion diagnostic implementation.
Main Methods:
- Review of historical drug and companion diagnostic case studies.
- Analysis of market situations and commercialization strategies for drugs requiring diagnostics.
- Evaluation of drugs launched with and without companion diagnostics, including post-launch implementation.
Main Results:
- Companion diagnostics are not universally beneficial or detrimental; their utility depends on specific contexts.
- Case studies show companion diagnostics can significantly benefit drug developers (e.g., Iressa, statins).
- Other case studies highlight pitfalls to avoid, offering lessons for strategic implementation (e.g., Accutane, Clozaril).
Conclusions:
- Drug developers can gain insights into companion diagnostic strategies by evaluating historical successes and failures.
- Understanding specific market situations is crucial for determining the appropriate companion diagnostic strategy.
- Developing a successful companion diagnostic strategy requires careful consideration of past experiences and tailored approaches.
Related Concept Videos
01:20Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:24Automated Microbial Diagnostics
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...